However, weight loss achieved through lifestyle interventions and GLP-1- or SGLT-2-based therapies may permit discontinuation of medications that promote weight gain and/or hypoglycemia (e.g., sulfonylureas, glinides, pioglitazone, and insulin) or that lack CV or renal benefits (all the aforementioned plus DPP-4 inhibitors) [24,70]. This evidence concerns the gene INS and Hypoglycemia.